Literature DB >> 23238504

Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.

S Salmenkylä1, M Kouri, P Österlund, E Pukkala, P Luukkonen, M Hyöty, M Pääkkönen, J Mäkelä, H Mustonen, H J Järvinen.   

Abstract

BACKGROUND AND AIMS: In a randomized trial the effect of short-term preoperative radiotherapy and postoperative chemotherapy was studied in patients undergoing total mesorectal excision (TME) for clinically resectable rectal cancer. The primary endpoint was overall survival. The secondary endpoints published herein were the incidence of postoperative complications and adverse events with perioperative adjuvant therapy.
MATERIAL AND METHODS: In 1995-2002, 278 eligible patients with stage II and stage III rectal cancer were randomly assigned to TME alone (surgery group) or to preoperative 25 Gy radio-therapy in 5 fractions and postoperative 5-fluorouracil and leucovorin chemotherapy in addition (RT+CT group).
RESULTS: Anastomotic leakage rate did not significantly differ between the surgery and the RT + CT group, 20.6% vs. 27.4%. Postoperative infections (15.5 vs. 26.2%, p = 0.037) and perineal wound dehiscence (15.9 vs. 38.5%, p = 0.045) were more common after radiotherapy. Grade 3-5 adverse events were uncommon with preoperative radiotherapy (one, 0.7% with reversible lumbar plexopathy) and postoperative chemotherapy (hematologic in 10.8%, with one septic death, and gastrointestinal in 4.8%).
CONCLUSIONS: Perioperative adjuvant therapy was generally well tolerated and did not lead to an increase in serious surgical complications. Wound infections and perineal wound dehiscence were more common in irradiated patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238504     DOI: 10.1177/145749691210100410

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  6 in total

1.  Short-Term and Long-Term Outcomes in Mid and Low Rectal Cancer With Robotic Surgery.

Authors:  Jingwen Chen; Zhiyuan Zhang; Wenju Chang; Tuo Yi; Qingyang Feng; Dexiang Zhu; Guodong He; Ye Wei
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

2.  Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.

Authors:  Marijn Koëter; Maurice J C van der Sangen; Coen W Hurkmans; Misha D P Luyer; Harm J T Rutten; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2015-03-06       Impact factor: 3.481

Review 3.  Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064).

Authors:  Felix J Hüttner; Pascal Probst; Eva Kalkum; Matthes Hackbusch; Katrin Jensen; Alexis Ulrich; Markus W Büchler; Markus K Diener
Journal:  Syst Rev       Date:  2018-01-22

Review 4.  Current applications and future prospects of nanomaterials in tumor therapy.

Authors:  Yu Huang; Chao-Qiang Fan; Hui Dong; Su-Min Wang; Xiao-Chao Yang; Shi-Ming Yang
Journal:  Int J Nanomedicine       Date:  2017-03-07

5.  Effects of Neoadjuvant Radiotherapy on Postoperative Complications in Rectal Cancer: A Meta-Analysis.

Authors:  Jianguo Yang; Yajun Luo; Tingting Tian; Peng Dong; Zhongxue Fu
Journal:  J Oncol       Date:  2022-01-05       Impact factor: 4.375

Review 6.  Adjuvant chemotherapy.

Authors:  B Glimelius
Journal:  EJC Suppl       Date:  2013-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.